UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes

CPT: pharmacometrics and systems pharmacology, 2024-07, Vol.13 (7), p.1214-1223

2024

Volltextzugriff (PDF)

Optimization of trial duration to predict long‐term HbA1c change with therapy: A pharmacometrics simulation‐based evaluation

CPT: pharmacometrics and systems pharmacology, 2022-11, Vol.11 (11), p.1443-1457

2022

Volltextzugriff (PDF)

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1521-1528

2017

Volltextzugriff (PDF)

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Diabetes care, 2016-07, Vol.39 (7), p.1241-1249

2016

Volltextzugriff (PDF)

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation

Paediatric drugs, 2023-05, Vol.25 (3), p.377-387

2023

Volltextzugriff (PDF)

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Cell metabolism, 2023-02, Vol.35 (2), p.274-286.e10

2023

Volltextzugriff (PDF)

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.751-767

2023

Volltextzugriff (PDF)

Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes

Journal of diabetes science and technology, 2023-03, Vol.17 (2), p.274-282

2023

Volltextzugriff (PDF)

348-P: Nasal Glucagon Was Efficacious in Reversing Insulin-Induced Hypoglycemia across a Range of Nadir Blood Glucose Levels

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Development and Qualification of a Drug‐Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials

Clinical pharmacology and therapeutics, 2018-10, Vol.104 (4), p.699-708

2018

Volltextzugriff (PDF)

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2017-08, Vol.19 (8), p.1071-1077

2017

Volltextzugriff (PDF)

Insulin, Not the Preservative m-cresol, Instigates Loss of Infusion Site Patency Over Extended Durations of CSII in Diabetic Swine

Journal of pharmaceutical sciences, 2021-03, Vol.110 (3), p.1418-1426

2021

Volltextzugriff (PDF)

A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development

Clinical pharmacokinetics, 2016-07, Vol.55 (7), p.769-788

2016

Volltextzugriff (PDF)

Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes

Journal of diabetes science and technology, 2021-09, Vol.15 (5), p.1195-1197

2021

Volltextzugriff (PDF)

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Diabetes care, 2014-09, Vol.37 (9), p.2609-2615

2014

Volltextzugriff (PDF)

Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus

Diabetes, obesity & metabolism, 2018-05, Vol.20 (5), p.1193-1201

2018

Volltextzugriff (PDF)

Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

Diabetes, obesity & metabolism, 2018-02, Vol.20 (2), p.419-426

2018

Volltextzugriff (PDF)

Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2017-11, Vol.19 (11), p.1521-1528

2017

Volltextzugriff (PDF)

Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response

Journal of diabetes science and technology, 2018-01, Vol.12 (1), p.155-162

2018

Volltextzugriff (PDF)

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Diabetes care, 2017-06, Vol.40 (6), p.808-808

2017

Volltextzugriff (PDF)

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Diabetes care, 2016-11, Vol.39 (11), p.e199-e200

2016

Volltextzugriff (PDF)

Novel hepato‐preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes

Diabetes, obesity & metabolism, 2017-04, Vol.19 (4), p.482-488

2017

Volltextzugriff (PDF)

Static/Dynamic Bifurcation and Chaotic Behavior of an Ethanol Fermentor

Industrial & engineering chemistry research, 2004-03, Vol.43 (5), p.1260-1273

2004

Volltextzugriff (PDF)

Non-linear characteristics of a membrane fermentor for ethanol production and their implications

Nonlinear analysis: real world applications, 2006-07, Vol.7 (3), p.432-457

2006

Volltextzugriff (PDF)

Bifurcation analysis of two continuous membrane fermentor configurations for producing ethanol

Chemical engineering science, 2004-08, Vol.59 (15), p.3235-3268

2004

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)

Publikationsform

Artikel
(31)
Buchkapitel
(2)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(17)
Humans
(15)
Diabetes
(12)
Endocrinology & Metabolism
(10)
Adult
(9)
Glucose
(9)
Insulin
(9)
Diabetes Mellitus, Type 2 - Drug Therapy
(8)
Male
(8)
Engineering
(7)
Female
(7)
Hypoglycemic Agents - Therapeutic Use
(7)
Middle Aged
(7)
Pharmacology & Pharmacy
(7)
Technology
(7)
Cross-Over Studies
(6)
Engineering, Chemical
(6)
Hypoglycemic Agents - Administration & Dosage
(6)
Hypoglycemic Agents - Adverse Effects
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes

Optimization of trial duration to predict long‐term HbA1c change with therapy: A pharmacometrics simulation‐based evaluation

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes

348-P: Nasal Glucagon Was Efficacious in Reversing Insulin-Induced Hypoglycemia across a Range of Nadir Blood Glucose Levels

Development and Qualification of a Drug‐Disease Modeling Platform to Characterize Clinically Relevant Endpoints in Type 2 Diabetes Trials

Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes

Insulin, Not the Preservative m-cresol, Instigates Loss of Infusion Site Patency Over Extended Durations of CSII in Diabetic Swine

A Comprehensive Review of Novel Drug–Disease Models in Diabetes Drug Development

Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus

Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249

Novel hepato‐preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes

Static/Dynamic Bifurcation and Chaotic Behavior of an Ethanol Fermentor

Non-linear characteristics of a membrane fermentor for ethanol production and their implications

Bifurcation analysis of two continuous membrane fermentor configurations for producing ethanol

Aktive Filter

Suchergebnisse filtern